1.74
8.07%
+0.13
After Hours:
1.60
-0.14
-8.05%
Connect Biopharma Holdings Ltd ADR stock is currently priced at $1.74, with a 24-hour trading volume of 469.57K.
It has seen a +8.07% increased in the last 24 hours and a +47.46% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.53 pivot point. If it approaches the $1.84 resistance level, significant changes may occur.
Connect Biopharma Holdings Ltd ADR Stock (CNTB) Financials Data
Connect Biopharma Holdings Ltd ADR (CNTB) Net Income 2023
CNTB net income (TTM) was -$85.88 million for the quarter ending June 30, 2023, a +65.93% increase year-over-year.
Connect Biopharma Holdings Ltd ADR (CNTB) Cash Flow 2023
CNTB recorded a free cash flow (TTM) of -$80.96 million for the quarter ending June 30, 2023, a -23.27% decrease year-over-year.
Connect Biopharma Holdings Ltd ADR (CNTB) Earnings per Share 2023
CNTB earnings per share (TTM) was -$1.5686 for the quarter ending June 30, 2023, a +69.12% growth year-over-year.
Connect Biopharma Holdings Ltd ADR Stock (CNTB) Latest News
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
GlobeNewswire Inc.
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
Zacks Investment Research
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Benzinga
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
GlobeNewswire Inc.
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
GlobeNewswire Inc.
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
About Connect Biopharma Holdings Ltd ADR
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with AD. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):